Agenda

Opening Remarks

Conference Chair: Leandro Gandos - Health Economist - Swiss TPH

Built For Uncertainty: The New Operating Model for Global Pricing & Market Access

• Explores how pricing & access competencies and structure should evolve to stay resilient under MFN and HTA pressure.
• Widens the frame beyond MFN alone to the broader pattern of uncertainty hitting pricing teams, including supply chain disruption and other shocks, and what that demands in terms of agility.
• Walk away with a practical view of the skills, processes, and organizational design choices that separate agile pricing functions from those caught off guard.

Ivan Grishchenko - Global Pricing Director - Novo Nordisk

How MFN and AI are Reshaping Price & Access

• Two of the most consequential impacts on price & access in our lifetime are upon us. What do they mean for professionals in everyday work?
• MFN is the most consequential price & access policy ever implemented.
• At the same time, AI is reshaping both pharma and payer execution of price & access.
• What does the future intersection of these two massive global changes mean for Price & Access Professionals?

Alan Crowther - General Manager - EVERSANA

Geopolitical Chaos, Budget Freezes, and Supply Chain Shocks: How Are Pricing Teams Actually Coping?

• Panellists share their real pricing war-room set-ups: who is in the room, how often, what triggers a scenario review?
• The Middle East conflict, Ukraine, and oil prices: how global instability is changing commercial strategy at the country level.
• Learn with senior leaders what decisions did they get wrong in the last 18 months, and what would they do differently?

Karan Suri - Senior Director of Global Pricing - World CourierSilvia Antonelli - Senior Director Price Reimbursement and Access - Eli LillyDaniela Campos - Senior Global Strategic Access & Pricing - Boehringer IngelheimModerator: Leandro Gandos - Health Economist - Swiss TPH

How AI Can Optimize the Pricing and Tenders/Contracting Performance for Pharma and Life Science Companies-Real Use Case Examples:

• Focuses on unresolved industry problem on manually intensive work prone to errors and lacking efficiency in tender/contract responses including lack of harmonized data.
• Concrete example on decision, efficiency improvements through AI usage.

Kaushal Kishore - Global Tender and Pricing Lead - Fresenius Kabi

From Product Pricing to Intelligence Pricing

• When products become connected, every therapy, device, and patient interaction generates data. Combined with rapidly advancing AI capabilities, the question is no longer whether that data has value, but who captures and monetizes it.
• Discover how leading life sciences organizations are moving beyond products and services to monetize insights, outcomes, and decision support for providers, payers, and healthcare systems.
• Understand the strategic choices, capabilities, and governance required to build a sustainable data monetization model without compromising trust or access.

Maarten Moreels - Partner Commercial Strategy & Pricing - EY-ParthenonThomas Aerts - Director Commercial Strategy & Pricing - EY-Parthenon

Turning MFN Into Momentum: What the Swiss–Mena Model Offers The Industry

• Discover the Swiss-MENA bridge model Labatec built before MFN existed, and what makes it a credible blueprint other companies can replicate today.
• Understand MENA's real commercial upside in the MFN era: the growth trajectory and access windows most global pricing teams are still overlooking.
• See the pricing-shield mechanism in action: how a MENA-first sequence protected EU and Swiss pricing, and what those markets would look like today without it.
• Walk away knowing what you need before you commit to MENA: the commercial, regulatory, and pricing prerequisites that determine whether this model fits your portfolio.

Alexandra Hoos - Market Access Lead - Labatec Pharma

From Negotiation to Partnership: The Mindset Shift That Unlocks Value

• From product price to pathway value: how to quantify what your treatment does to the whole care system in a language payers can no longer dismiss.
• Affordability as a design principle, not a concession: why companies that build sustainable pricing models from the patient and system perspective up are gaining access their competitors are losing.
• Shape it or have it forced on you: the honest conversation about where the industry-payer relationship has to go next — and what you personally have to change to get there.

RESERVED VISTEX

Pick Your Problem: Peer-Led Deep Dives on the Challenges Keeping You Awake

Choose the table that matches your most pressing challenge.

Price & Access in An AI-Driven World: Is Your Function Ready Or Just Talking About It?

• Panellists reveal where they honestly sit on the AI maturity curve — and what the gap between aspiration and reality looks like.
• The generational problem: tech-native junior staff can prompt, but can they judge? Senior staff can judge, but can they prompt?

Antoon Boussu - Global Pricing Lead - Novo NordiskMarco Raddi - Global Pricing Analyst - Chiesi

Day 2 Opening — Insights from Day 1 Research Summary

Forum Chair opens with synthesised themes from Day 1 discussions — practitioner perspectives anonymised and aggregated in real time.

Explore How Innovative Contracting Can Open New Opportunities

• Understand the structural barriers that make outcomes-based and risk-sharing contracts collapse before they scale such as data gaps, legal complexity, and misaligned incentives.
• Explore the full menu of contracting options available today: annuity models, volume caps, outcome milestones, and managed entry agreements, with honest assessments of each.
• Learn what is changing in the operating environment that could finally make innovative contracting the default, not the exception.

Matthias Struebe - Global Pricing Leader - Roche

Building Real-Time Commercial Intelligence When Market Volatility Demands Faster Decisions – A Case Study With AAH

Generic drug prices move like commodities. Rebate terms shift constantly. Customer negotiations are growing more complex. We'll walk through a real case where AAH, a major pharmaceutical wholesaler, moved from spreadsheet-based pricing to unified commercial intelligence that enabled faster negotiations, better pricing decisions, and 12% volume growth even in a margin-pressured market.

• Why unified pricing visibility matters more now than ever and what you're missing if pricing lives across disconnected systems.
• How modernizing pricing infrastructure delivered £2M in margin recovery and 35x ROI in a business managing over 18,000 pricing agreements.

Ranjit Gill - CIO - AAHAJ Kruijer - Strategic Account Executive - Enable

Rethinking Your Launch Sequencing: How To Rebuild Your Global Go-To-Market Logic

• Re-think the traditional sequencing model, as it no longer fully protects price architecture under MFN and IRP pressure.
• Navigate the new sequencing trade-offs: speed vs. price protection, access vs. reference risk, and early-launch markets vs. strategically important markets.
• Make launch decisions today for a future pricing and policy landscape that remains highly unpredictable.

Daniela Campos - Senior Global Strategic Access & Pricing - Boehringer Ingelheim

Pick Your Problem: Peer-Led Deep Dives on the Challenges Keeping You Awake

Choose the table that matches your most pressing challenge.

ROI - Reframing the Economics Of Patient Adherence In Cardiometabolic Care

• The €125 billion question: how non-adherence in chronic cardiometabolic conditions contributes to a substantial and often under-recognized burden for patients, healthcare systems and society across Europe, and what data reveals about where costs accrue.
• From pill burden to pricing strategy: how single-pill combinations may simplify treatment for multimorbid patients, and the challenges of assessing value beyond the individual components of treatment.
• Broadening the payer perspective: exploring how real-world adherence evidence can enrich discussions around cost-effectiveness, budget impact, ROI, and the cost of inaction.

Parlato Gianfranco - Global Head of Value Access, Pricing & Policy, CardioMetabolic & Venous Diseases - Servier

The Skills Gap Nobody Talks About: Why Your Pricing Strategy Fails Without Soft Skills

• Understand why storytelling, stakeholder influence, and change management are now core pricing competencies, not optional extras.
• The generational problem in pricing teams: senior experience without digital fluency meets digital fluency without business judgment, and how to bridge the gap deliberately.
• Build the internal capability to get C-suite buy-in for pricing decisions that are technically correct but commercially invisible without the right narrative.

Silvia Antonelli - Senior Director Price Reimbursement and Access - Eli Lilly

When the Payer Runs Out of Money: Pricing in an Era of Permanent Budget Pressure

• European healthcare budgets are not temporarily constrained — they are structurally limited. What that means for every negotiation you will have in the next five years.
• How payers are changing their decision criteria when budgets freeze: what still gets funded, what gets cut, and what gets delayed indefinitely.
• Adapt your value story for a payer audience that has stopped asking "does it work?" and started asking "can we afford it?"

Reserved for MD

Pricing Under Permanent Uncertainty: A Scenario Playbook for the MFN Era

• Build a scenario-planning framework that holds up no matter which version of MFN actually lands — and know your organization's risk tolerance before you're forced to decide under pressure.
• What the EU's new launch-window rules mean to you.

Catarina Pinheiro - Head of Global Pricing - Ferrer International

What Will the Pricing Function Look Like in 2030? A Provocative Forecast

• AI will not eliminate pricing jobs — but it will eliminate pricing roles that fail to evolve. Here is the evolution map.
• The skills gap is real and getting worse: multidisciplinary talent who understand data, pharma, and AI simultaneously does not exist yet at scale.
• Your 2030 team will be smaller, faster, and more influential — if you start building it now. Here is where to start.